Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

The investment comes as the FDA is pushing drug developers to phase out animal testing in some of the biologic treatments ...

On a positive note, ivonescimab, when used alongside chemotherapy, reduced the risk of disease progression or mortality by 48 ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

The French pharmaceutical giant is acquiring a Cambridge biotech and its rare immunology disease which is already approved in ...

Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, expanding its immunology pipeline ...

SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation , and Evosep Biosystems, a global leader in proteomics solutions, enter a reseller agreement ...

SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation , announces three software ecosystem enhancements at ASMS. These developments will present ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost ...

As part of its enforcement activities, the Food and Drug Administration sends warning letters to entities under its ...